Physician profile
Amanda K Smith
NPI 1831328343
$2,704.67
in general payments reported to CMS, 2019-2025
25 companies · $850 in 2025
The $850 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $206 · 2020: $103 · 2021: $75.30 · 2022: $135 · 2023: $571 · 2024: $765 · 2025: $850.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,166 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,166.40 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $577.75 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $470.01 | 2022-2025 | Mounjaro, Zepbound, Kisunla |
| Novo Nordisk INC | $391.45 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $271.82 | 2022-2025 | Vraylar |
| Bayer Healthcare Pharmaceuticals INC. | $217.49 | 2022-2025 | |
| Glaxosmithkline, LLC. | $179.77 | 2023-2025 | Trelegy Ellipta |
| Mylan Specialty L.P. | $61.23 | 2023-2024 | Yupelri |
| Axsome Therapeutics, INC. | $60.09 | 2025 | Auvelity |
| Stimwave Technologies Incorporated | $46.68 | 2021 | |
| Exact Sciences Corporation | $45.09 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Amgen INC. | $43.01 | 2023 | Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $41.02 | 2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $38.57 | 2024-2025 | Trintellix |
| Esperion Therapeutics, INC. | $29.18 | 2021-2024 | Nexletol |
| Pfizer INC. | $28.15 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.91 | 2019 | |
| Idorsia Pharmaceuticals US INC | $26.45 | 2022-2023 | Quviviq |
| Xeris Pharmaceuticals, INC. | $23.87 | 2024 | Gvoke Hypopen |
| Medtronic, INC. | $22.32 | 2022 | |
| Janssen Pharmaceuticals, INC | $22.14 | 2019 | |
| Sanofi-Aventis U.S. LLC | $21.14 | 2020 | |
| Novartis Pharmaceuticals Corporation | $18.90 | 2024 | |
| Sage Therapeutics, LLC | $16.72 | 2025 | Zurzuvae |
| Astellas Pharma US INC | $15.26 | 2024 | Veozah |
| Phathom Pharmaceuticals, INC. | $8.65 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.